Pulsed low-dose-rate radiation plus chemotherapy versus standard chemoradiation for esophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, open-label phase 2 trial assigns adults with locally advanced esophageal adenocarcinoma to receive either pulsed low-dose-rate (PLDR) radiation or conventional radiation, each given with standard concurrent chemotherapy and possible esophagectomy. PLDR delivers the same total radiation dose as standard treatment but in a series of small pulses separated by timed pauses, which may reduce normal tissue injury. The trial's primary focus is rates of clinically significant esophagitis during and after chemoradiation, with safety, feasibility, and oncologic outcomes also monitored. Eligible participants must have ECOG 0–2 and adequate blood, liver, and kidney function and will be treated at Froedtert & the Medical College of Wisconsin.

Why it matters

Who can join: the full rules

Inclusion Criteria:

A potential study subject who meets all of the following inclusion criteria is eligible to participate in the study.

1. Age ≥ 18 years.
2. Stage II-IVb adenocarcinoma of the esophagus (if IVb, oligometastatic only, felt to be eligible for definitive dose CRT treatment by treating physician).
3. Currently receiving or have received induction chemotherapy and planned for definitive dose chemoradiation (+/- esophagectomy).
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
5. Adequate hematologic function within 30 days prior to registration defined as follows:

   1. Absolute Neutrophil Count ≥ 1,500/mcg
   2. Hemoglobin ≥ 8 gm/dL
   3. Platelets ≥ 100,000/mcL.
6. Adequate renal function within 30 days prior to registration, defined as a creatinine clearance of ≥ 50 ml/min as calculated by the Cockcroft-Gault equation.
7. Adequate hepatic function within 30 days prior to registration, defined as total bilirubin ≤ 1.5 x ULN

   a. Note: patients with known Gilbert Syndrome can have a total bilirubin \< 2.5 x upper limit of normal (ULN).
8. Female patients \<65 years of age and of childbearing potential must have a negative serum/urine pregnancy test within 14 days prior to study entry. A female not of childbearing potential is one who has undergone a hysterectomy, bilateral oophorectomy, tubal ligation, or who has had no menses for 12 consecutive months.
9. Patients of reproductive potential must agree to use effective contraception for the duration of study treatment. Effective contraception includes oral contraceptives, implantable hormonal contraception, double-barrier method, or intrauterine device.
10. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
11. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

A potential study subject who meets any of the following exclusion criteria is ineligible to participate in the study.

1. Age \< 18 years.
2. Extensive distant metastatic cancer, defined as \>5 metastases.
3. Recurrent esophageal cancer.

   a. Note: prior or concurrent malignancies are allowed if they do not impact the study's primary endpoint (i.e., treatment-associated toxicity).
4. Prior non-approved chemotherapy for the treatment of cancer.
5. Prior radiotherapy to the region of the study cancer that would result in an overlap of radiation therapy fields.
6. Women must not be pregnant or breast-feeding.

Where it's running

• Froedtert & the Medical College of Wisconsin
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Lindsay Puckett, MD — Medical College of Wisconsin
• Study coordinator: Medical College of Wisconsin Cancer Center Clinical Trials Office
• Email: cccto@mcw.edu
• Phone: 866-680-0505

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• Evaluating zanidatamab for HER2-expressing tumors

  This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.

  Recruiting at 30 sites Phase 2 Jazz Pharmaceuticals · Prescott, Arizona and 41 other locations · NCT06695845

• Reducing dosing frequency of immune checkpoint inhibitors in advanced cancers

  This study is testing if giving immune checkpoint inhibitors less often can still help people with advanced cancers feel better while making treatment easier and cheaper.

  Recruiting Phase 2 National University Hospital, Singapore · Singapore · NCT06422403

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• Combining PD-1 inhibitor with chemoradiotherapy and surgery for esophageal cancer

  This study is testing if adding a new drug to standard treatment before surgery can help people with advanced esophageal cancer live longer and feel better.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT05357846

• Combining chemotherapy and immunotherapy for esophageal cancer treatment

  This study is testing if combining immunotherapy with chemotherapy can help improve survival for patients with esophageal cancer who had surgery but are at high risk of their cancer coming back.

  Recruiting The Second Hospital of Shandong University · Jinan, Shandong · NCT04688801

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.